cd46 protein, multiple sclerosis EU researchers unveil how T cell dysfuncti...French and British scientists have revealed insight into how a critical immune regulatory pathway contributes to the development of multiple sclerosis (MS), potentially paving the way toward future immunotherapies … more ➔
Uniqure readies share stock offering Dutch Uniqure BV launched a public offering of five million shares of common stock. Underwriters over-allotment will be an additional 750,000 shares. more ➔
bioethanol, biofuel Biofuels: study challenges EU’s tank...A comprehensive sustainability assessment carried out by Cologne-based nova-Institute shows that first and second-generation bioethanol is feasible for the EU’s climate strategy. The study challenges … more ➔
ADC Therapeutics raises US$200m in private... Swiss cancer antibody-drug conjugate (ADC) developer ADC Therapeutics Sarl (Epalinges) has raised US$200m million through an oversubscribed private placement. Investors include Auven Therapeutics, … more ➔
bioeconomy, EuropaBio, European Biotech week Valuating biotech’s benefitsEuropean Biotech Week:?Highlighting the benefits biotechnology has brought to pharma development, agriculture and – last but not least – the bioeconomy, industry association EuropaBio celebrated … more ➔
CureVac inks $1.7bn deal on mRNA cancer va...mRNA cancer therapeutics specialist CureVac AG has baged US$50m upfront and is eglible to receive up to US$1.7bn in development milestones plus royalties for the development of five commercial cancer … more ➔
Ablynx prices global offeringBelgian Nanobody® producer Ablynx NV said it aims to raise US$175m of its ordinary shares in a global offering, comprised of a public offering of American Depositary Shares ("ADS") in the … more ➔
HPV vaccines: Cochrane Centre’s comp...A complaint against the EMA’s handling of a referral procedure relating to potential side effects of Sanofi/MSD’s HPV vaccine Gardasil and GSK’s HPV jab Cervarix promoted by the Nordic Cochrane … more ➔
CHMP upgrades Roche’s lung cancer dr...The European Medicines Agency (EMA) has upgraded Roche’s Alecensa (Alectinib) from second-line to first-line treatment for patients with locally advanced of metastasing ALK-positive non-small cell lung … more ➔
InflaRX raises US$55m in Series D roundGerman infection specialist InflaRx (Jena) raised US$55m in a Series D financing co-led by Bain Capital Life Sciences LP, Cormorant Asset Management LLC and RA Capital Management LLC to finance … more ➔
